Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors

Shunrong Ji,Mengqi Liu,Huanyu Xia,Zeng Ye,Xiaowu Xu,Xianjun Yu,Qifeng Zhuo

DOI: https://doi.org/10.1097/mpa.0000000000001705

2021-01-01

Pancreas

Abstract:Ji, Shunrong MD; Liu, Mengqi MD; Xia, Huanyu BD; Ye, Zeng MD; Xu, Xiaowu MD; Yu, Xianjun MD; Zhuo, Qifeng MD Author Information

What problem does this paper attempt to address?

Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An analysis of the US SEER Database and a Chinese Single-center Cohort

Shunrong Ji,Mengqi Liu,Zeng Ye,Xiaowu Xu,Xianjun Yu,Qifeng Zhuo

DOI: https://doi.org/10.21203/rs.3.rs-17909/v1

2020-01-01

Abstract:Background. Nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) are often small, slow growing, clinically silent neoplasms. Currently, ‘wait-and-see’ policy is recommended by the European Neuroendocrine Tumor Society (ENETS) for NF-pNETs (<2 cm). But the scientific basis for such recommendation is scarce. Methods. Data of NF-pNETs cases were reviewed retrospectively from the Surveillance, Epidemiology, and End Result (SEER) database during 2004-2015. Statistic description and survival analysis were done. Patients who underwent surgery for NF-pNET in our center during 2010-2018 were identified and analyzed retrospectively. Results. 1828 NF-pNET with tumor size between 1-4cm were identified in SEER database. Observation was recommended for 172 patients (9.4%). 1656 patients received surgery. The observation group was significantly older and mainly with tumor located in pancreatic head. There was no survival difference between the two groups with NF-pNET ≤2 cm. Median survival time was significantly longer in surgery group with NF-pNET >2 cm. 143 NF-pNETs with tumor size between 1-4cm were identified in our center. Conclusion. In selected older patients, nonoperative management of asymptomatic small NF-pNETs is safe. Preoperative grading with EUS-FNA may be a good option for making practice decision. Larger and prospective multicentric studies with long-term follow-up are now needed to validate this wait-and-see policy.
Consensus of Clinical Diagnosis and Treatment for Non-Functional Pancreatic Neuroendocrine Neoplasms with Diameter <2 Cm

Wenming Wu,Shouwang Cai,Rufu Chen,Deliang Fu,Chunlin Ge,Chunyi Hao,Jihui Hao,Heguang Huang,Zhixiang Jian,Gang Jin,Fei Li,Haimin Li,Shengping Li,Weiqin Li,Yixiong Li,Tingbo Liang,Xubao Liu,Wenhui Lou,Yi Miao,Yiping Mou,Chenghong Peng,Renyi Qin,Chenghao Shao,Bei Sun,Guang Tan,Huaizhi Wang,Lei Wang,Wei Wang,Weilin Wang,Junmin Wei,Heshui Wu,Zheng Wu,Changqing Yan,Yinmo Yang,Xiaoyu Yin,Xianjun Yu,Chunhui Yuan,Yupei Zhao

DOI: https://doi.org/10.1097/jp9.0000000000000139

2023-01-01

Journal of Pancreatology

Abstract:In clinical practice, pancreatic neuroendocrine neoplasms (pNENs) with a diameter smaller than 2 cm are commonly referred to as small pNENs. Due to their generally favorable biological characteristics, the diagnosis and treatment of small pNENs differ from other pNENs and are somewhat controversial. In response to this, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association have developed a consensus on the diagnosis and treatment of small pNENs, which is based on evidence-based medicine and expert opinions. This consensus covers various topics, including concepts, disease assessment, treatment selection, follow-up, and other relevant aspects.
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Guang Yang,Meng Ji,Jie Chen,Rufu Chen,Ye Chen,Deliang Fu,Baohua Hou,Heguang Huang,Liming Jiang,Kaizhou Jin,Nengwen Ke,Ying Li,Yong Li,Houjie Liang,An'an Liu,Jie Luo,Quanxing Ni,Chengwei Shao,Boyong Shen,Weiqi Sheng,Bin Song,Jian Sun,Chunlu Tan,Huangying Tan,Qiyun Tang,Yingmei Tang,Xiaodong Tian,Jian Wang,Jie Wang,Wei Wang,Zheng Wu,Jin Xu,Qiang Yan,Ning Yang,Yinmo Yang,Xiaoyu Yin,Xianjun Yu,Chunhui Yuan,Shan Zeng,Guochao Zhang,Renchao Zhang,Zhiwei Zhou,Zhaohui Zhu,Chenghao Shao

DOI: https://doi.org/10.3892/ijo.2016.3826

Abstract:The incidence of small (≤2 cm), non-functioning pancreatic neuroendocrine tumors (NF-pNETs) increased in the last decades. Before making appropriate strategy for patients with NF-pNETs ≤2 cm, pathological confirmation is vital. Incidentally diagnosed, sporadic small NF-pNETs may bring aggressive behavior and poor prognosis, such as extrapancreatic extension, lymph nodal metastasis, distant metastasis and recurrence, even causing disease-related death. Understanding and formulating an appropriate strategy for the patients with sporadic small, non-functioning pancreatic neuroendocrine tumors have been controversial for some time. Although several studies have reported that patients with NF-pNETs ≤2 cm had less rate of malignant behavior compared with larger ones (>2 cm); and the surgery approach may leading to surgery-related pancreatic complications; but there is still a lack of level I evidence to convince surgeons to abandon all cases with sporadic small NF-pNETs. Based on an updated literature search and review, the members of the Chinese Study Group for Neuroendocrine Tumors (CSNET) from high-volume centers have reached a consensus on the issue of the management strategy for the sporadic small NF-pNETs. We recommend that, except for some selected patients with NF-pNETs <1 cm, incidentally discovered and unacceptable surgical risks, all others with NF-pNETs ≤2 cm should undergo tumor resection with lymph node dissection or at least lymph node sampling and careful postoperative surveillance.
[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Ren-Chao Zhang,Yi-Ping Mou,Xiao-Wu Xu,Jia-Fei Yan,Qi-Long Chen

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2013.09.004

2013-01-01

Abstract:OBJECTIVE:To analyze the prognostic factors of pancreatic neuroendocrine neoplasms (PNEN).METHODS:Clinical data of 61 patients with PNEN from March 1992 to December 2012 was retrospectively analyzed. There were 23 male and 38 female patients, with a median age of 52 years (ranged from 22 to 68 years). Forty-one patients were non-functional tumors, and 20 patients were functional tumors. Fifty-nine patients received operation, 13 (22.0%) patients underwent laparoscopic operation, 2 patients underwent puncture biopsy under CT guidance. Survival was analyzed with the Kaplan-Meier method.RESULTS:Among these patients, 53 (86.9%) patients underwent curative resection. The cases of grade G1, G2, G3 were 41 (67.2%), 9 (14.8%), 11 (18.0%), respectively. The cases of stageI, II, III, IV were 47 (77.0%), 7 (11.5%), 2 (3.3%), 5 (8.2%), respectively. Liver metastasis, neural invasion were found in 5 cases (8.2%), 5 cases (8.2%), respectively. The median follow-up period was 40 months (ranged from 3 to 209 months). The overall 1-, 3-, 5-year survival rates were 92.0%, 89.7%, 86.3%, respectively. Univariate analysis showed WHO classification (χ(2) = 18.503), TNM staging system (χ(2) = 23.401), liver metastasis (χ(2) = 18.606), neural invasion (χ(2) = 10.091), resection status (χ(2) = 25.514) were prognostic factors of PNEN (all P = 0.000).CONCLUSIONS:Surgical resection in PNEN results in long-term survival. WHO classification, TNM staging, resection status are effective in predicting the prognosis of PNEN. Liver metastasis, neural invasion predicted poor prognosis.
Clinical Analysis and Comprehensive Treatment of Nonfunctional Pancreatic Neuroendocrine Tumor with Liver Metastases

Xuefeng Xu,Xu Han,Lingxiao Liu,Yuan Ji,Jianang Li,Wenhui Lou

DOI: https://doi.org/10.1097/mpa.0000000000000342

2015-01-01

Pancreas

Abstract:Xu, Xuefeng MD; Han, Xu MD; Liu, Lingxiao MD; Ji, Yuan MD; Li, Jianang MD; Lou, Wenhui MD Author Information
The surgical managements for neuroendocrine tumors of the pancreas

ZHUANG Yan,YANG Yin-mo

2010-01-01

Abstract:Neuroendocrine tumors of the pancreas comprise a variety of types with different characteristics. The rarity of these tumors renders the accumulation of clinical experience very slow and gives rise to the argument on the managements. Surgical managements, such as radical resection or debulking,play an important role in this field. Different procedures could be applied to different tumors with different types, different locations, and different developing stages. Different surgeon would make different decisions to select procedure for certain disease.
Risk Of Malignancy And Prognosis Of Sporadic Resected Small (<= 2 Cm) Nonfunctional Pancreatic Neuroendocrine Tumors

Xi Liu,Wenjie Chin,Chenggeng Pan,Weichen Zhang,Jun Yu,Shusen Zheng,Yuanxing Liu

DOI: https://doi.org/10.21037/gs-20-582

2021-01-01

Gland Surgery

Abstract:Background: Small nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) <= 2 cm have variable biological features, and there is no gold standard treatment for their management. The present study aimed to evaluate the risk of malignancy of small NF-PNETs and their outcomes following curative resection.Methods: Patients with NF-PNETs undergoing surgical resection at the First Affiliated Hospital, College of Medicine, Zhejiang University, between 2012 and 2017 were included. Clinicopathological characteristics, perioperative results, and prognosis were retrospectively analyzed.Results: A total of 73 patients were identified, including 28 with small NF-PNETs and 45 large PNETs; 32.1% of NF-PNETs <= 2 cm underwent a parenchyma-sparing pancreas surgery, which was >6.7% in large NF-PNETs. No statistically significant differences in perioperative results, postoperative complications, and long-term outcomes were found between small tumors undergoing standard and parenchyma-sparing pancreatectomy. Eighteen small tumors (64.3%) developed a perioperative complication, with a clinically significant pancreatic fistula rate of 25%; however, only 2 patient needed reintervention. Small NF-PNETs in 3 patients were malignant. Multivariate logistic regression showed that grade >= 3 and lymphovascular invasion were independently related to malignancy in NF-PNETs.Conclusions: Small NF-PNETs (<= 2 cm) are not immune from potential malignancy. Surgical resection may be considered for small tumors and can provide favorable postoperative and long-term outcomes. Parenchyma-sparing pancreatectomy may be an alternative surgery for selected small local NF-PNETs.
Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Kaizhou Jin,Jin Xu,Jie Chen,Minhu Chen,Rufu Chen,Ye Chen,Zhiyu Chen,Bin Cheng,Yihebali Chi,Shi-Ting Feng,Deliang Fu,Baohua Hou,Dan Huang,Heguang Huang,Qiang Huang,Jie Li,Ying Li,Houjie Liang,Rong Lin,An'an Liu,Jixi Liu,Xubao Liu,Ming Lu,Jie Luo,Gang Mai,Quanxing Ni,Meng Qiu,Chenghao Shao,Baiyong Shen,Weiqi Sheng,Jian Sun,Chunlu Tan,Huangying Tan,Qiyun Tang,Yingmei Tang,Xiaodong Tian,Danian Tong,Xiaohong Wang,Jian Wang,Jie Wang,Wei Wang,Yu Wang,Zheng Wu,Ling Xue,Qiang Yan,Ning Yang,Yinmo Yang,Zhiying Yang,Xiaoyi Yin,Chunhui Yuan,Shan Zeng,Renchao Zhang,Xianjun Yu

DOI: https://doi.org/10.3892/ijo.2016.3711

Abstract:Pancreatic neuroendocrine neoplasms (p-NENs) are slowly growing tumors with frequent liver metastasis. There is a variety of approaches to treat non-functional p-NENs with synchronous liver metastasis (LM) which complicates the determination of optimal treatment. Based on updated literature review, we discussed the treatment strategy determinants for p-NEN with LM. According to the resectability of primary tumor, the WHO 2010 grade classification and the radiological type of liver metastasis, the CSNET group reached agreements on a number of issues, including the following. Prior to treatment, biopsy is required to confirm pathology. Liver biopsy is important for more accurate grading of tumor and percutaneous core needle biopsy is more available than EUS-FNA. In patients with unresectable primary, surgical resection for liver-metastatic lesions should be avoided. Curative surgery is recommended for G1/G2 p-NET with type I LM and R1 resection also seems to improve overall survival rate. Cytoreductive surgery is recommended for G1/G2 p-NET with type II LM in select patients, and should meet stated requirements. Surgical resection for G1/G2 p-NET with type III LM and p-NEC with LM should be avoided, and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM. Liver transplantation may be an option in highly select patients. In addition, the optimal time for surgical approach is still required for more evidence.
Advances in Management of Nonfunctional Pancreas Neuroendocrine Tumors

Alexandra W. Acher,Julie Hallet

DOI: https://doi.org/10.1016/j.suc.2024.03.010

IF: 3.537

2024-04-25

Surgical Clinics of North America

Abstract:• Pancreas neuroendocrine tumors (PNETs) present a more indolent behavior than other pancreatic malignancies and require unique multidisciplinary assessment and discussions to form a therapeutic plan that may involve surgical, locoregional, and systemic approaches. • Advances in imaging and pathology for neuroendocrine neoplasms have allowed increasingly nuances assessment of disease biology to support decision-making and individualization of therapy. • Surgical management should be tailored to unique Pancreas neuroendocrine tumors (PNETs) present a more indolent behavior than other pancreatic malignancies and require unique multidisciplinary assessment and discussions to form a therapeutic plan that may involve surgical, locoregional, and systemic approaches. Advances in imaging and pathology for neuroendocrine neoplasms have allowed increasingly nuances assessment of disease biology to support decision-making and individualization of therapy. Surgical management should be tailored to unique

surgery
Analysis of the Clinical Features of 20 Cases of Non-Functioning Pancreatic Neuroendocrine Tumors

Yan Ge,Shen Shanmei,Bao Shanhua,Bi Yan,Zhu Dalong

DOI: https://doi.org/10.3760/cma.j.issn.1673-4904.2019.02.010

2019-01-01

Abstract:Objective To investigate the clinical features of non- functioning pancreatic neuroendocrine tumors and to summarize experiences in the diagnosis and treatment. Methods The clinical pathology and follow-up data of 20 patients with non-functioning pancreatic neuroendocrine tumors treated in Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, from January 2008 to February 2018 were retrospectively analyzed. Results Among the 20 patients, 9 patients (9/20) were asymptomatic, and the tumor was found unexpectedly by physical examination. Eleven patients (11/20) with symptoms were admitted to the hospital due to non-specific gastrointestinal symptoms or compression symptoms caused by tumor space occupying. None of the patients had endocrine disorders. There were nineteen patients who received surgical treatment. According to the grading system, there were 7 patients (7/19) with G1, and 12 patients (12/19) with G2 . Among the 14 patients with diameter of tumor greater than 2 cm, there are 4 patients (4/14) with lymph node metastasis, and 4 patients (4/14) with liver metastasis. Five patients with diameter of tumor less than or equal to 2 cm had no distant metastasis. Conclusions NF-pNETs is often with nonspecific symptoms. Imaging examination is an important diagnostic method. Operation is the primary therapy for NF-pNETs. Because most of the small NF-pNETs with no symptoms are benign and grow slowly, and the metastatic rate is very low. It is important to weigh the pros and cons of surgical treatment for these patients.
Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors

Ugo Marchese,Martin Gaillard,Anna Pellat,Stylianos Tzedakis,Einas Abou Ali,Anthony Dohan,Maxime Barat,Philippe Soyer,David Fuks,Romain Coriat

DOI: https://doi.org/10.3390/cancers14020433

2022-01-15

Abstract:Pancreatic neuroendocrine tumors (p-NETs) are rare tumors with a recent growing incidence. In the 2017 WHO classification, p-NETs are classified into well-differentiated (i.e., p-NETs grade 1 to 3) and poorly differentiated neuroendocrine carcinomas (i.e., p-NECs). P-NETs G1 and G2 are often non-functioning tumors, of which the prognosis depends on the metastatic status. In the localized setting, p-NETs should be surgically managed, as no benefit for adjuvant chemotherapy has been demonstrated. Parenchymal sparing resection, including both duodenum and pancreas, are safe procedures in selected patients with reduced endocrine and exocrine long-term dysfunction. When the p-NET is benign or borderline malignant, this surgical option is associated with low rates of severe postoperative morbidity and in-hospital mortality. This narrative review offers comments, tips, and tricks from reviewing the available literature on these different options in order to clarify their indications. We also sum up the overall current data on p-NETs G1 and G2 management.
Clinical Efficacy of the Laparoscopic Resection for Pancreatic Neuroendocrine Neoplasms

黄超杰,张人超,牟一平,严加费,周育成,金巍巍,吴迪,潘宇

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2014.10.007

2014-01-01

Abstract:Objective To investigate the clinical efficacy of laparoscopic resection for pancreatic neuroendocrine neoplasms (pNENs).Methods The clinical data of 31 patients who received laparoscopic resection for pNENs at the Sir Run Run Show Hospital of Zhejiang University from March 2005 to June 2014 were retrospectively analyzed.The surgical procedure was selected according to the location and size of the pNENs.Patients were followed up via phone call or out-patient examination till August 2014.Results Laparoscopic resection was successfully carried out on all the 31 patients,including laparoscopic enucleation in 4 patients,laparoscopic pancreatoduodenectomy in 2 patients,laparoscopic central pancreatectomy in 2 patients,laparoscopic spleenpreserving distal pancreatectomy in 6 patients and laparoscopic distal pancreatosplenectomy in 17 patients.The operation time,volume of intraoperative blood loss and blood transfusion rate were (205 ± 74)minutes,125 mL (10-1 000 mL) and 9.7％ (3/31),respectively.The time for out-off-bed activity,time to anal exsufflation,time for fluid diet intake and duration of postoperative hospital stay were 2 days (range,1-3 days),3 days (range,1-4 days),3 days (range,1-7 days) and 10 days (range,5-63 days).The incidence of postoperative complications was 35.5％ (11/31),and the complications were cured after symptomatic treatment.No patient died perioperatively.Thirty-one patients were followed up with the follow-up rate of 100.0％.The median time for followup was 21 months (range,5-111 months).One patient had symptom of pancreatic exocrine insufficiency after the operation; 3 patients had diabetes at postoperative month 1 ; 1 patient died of tumor metastases at postoperative year 1 ; 1 patient had Whipple's triad at postoperative year 3,and was confirmed with tumors in the head and tail of the pancreas by magnetic resonance imaging.No tumor recurrence or metastasis was detected in the other patients.Conclusions Laparoscopic resection is safe and feasible for the treatment of pNENs.The surgical procedure is selected based on the location and size of the pNENs.Laparoscopic resection of pNENs has the advantages of small trauma,quick recovery of the patients and favorable short-and long-term efficacy.
Minimal Invasive Surgery in the Treatment of Neuroendocrine Tumors of the Pancreas

Q C Zhu,Y P Mou

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2018.11.019

2018-01-01

Abstract:Neuroendocrine tumor of the pancreas (pNET) is a rare group of neoplasms with widely heterogeneity.Complete surgical resection remains the only potentially curative treatment for pNET.Compared to open surgery,minimal invasive approach treating pNET could decrease bleeding and shorten postoperative hospital stay,while didn't show difference in operation time,postoperative complication rate and overall mortality.Therapeutic strategy was formulated by synthesizing clinical symptoms,tumor size and tumor stage.Minimal invasive approach can achieve radical curve of oncology and provide refine manipulation condition to improve surgical safety and efficacy,meanwhile realize function preservation.Minimal invasive approach is a safe and efficient method in treating pNET,but further prospective,randomized control trials are required.
Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature

A Amador Cano,F García,A Espinoza,N Bezies,E Herrera,J De Leija Portilla

DOI: https://doi.org/10.1016/j.ijscr.2012.10.018

Abstract:Introduction: Pancreatic neuroendocrine tumors (PNET) have an incidence of one per 100,000 individuals per year. They represent about 1-2% of all pancreatic tumors. PNETs are a heterogeneous group with various clinical presentations and lineage. Non functional PNET (NF-PNET) are incidentally discovered in most cases. This article presents a review of NF-PNET and the case of a patient with this disease, in addition to its diagnosis, clinical presentation, and treatment. Presentation of case: The patient is a 37-year-old asymptomatic man who was sent from his reference unit because of a pancreatic tumor that was visualized incidentally during a laparotomy performed three months before due to an acute abdomen secondary to blunt abdominal trauma. A CT scan was requested that showed a retroperitoneal mass 7.5cm×6.6cm×7cm with infiltration of the duodenal wall. Endoscopy was performed, which reported a duodenal ulcer with nonconclusive histological findings. A percutaneous biopsy was obtained out and a diagnosis of a neuroendocrine tumor was made. Chemotherapy was started because infiltration of the portomesenteric axis was suspected. The patient presented signs of toxicity during his third cycle and therefore was scheduled for exploratory laparotomy. Pancreatoduodenectomy was performed with a histologic diagnosis of a pancreatic neuroendocrine tumor. Discussion: The presentation of a NF-PNET is nonspecific. They continue to be tumors with a low incidence and few studies directed toward early detection and management have been carried out. Currently, CT scans are the studies most used for detection. Conclusion: Surgical treatment is preferred in patients without evidence of unresectability with longer survival. The characteristics of NF-PNETs make their detection difficult and new strategies are needed for early detection and management. New studies in early stages with new cytotoxics or analogs are promising.
Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: an International Study Using Multi-Institutional Registries

In Woong Han,Jangho Park,Eun Young Park,So Jeong Yoon,Gang Jin,Dae Wook Hwang,Kuirong Jiang,Wooil Kwon,Xuefeng Xu,Jin Seok Heo,De-Liang Fu,Woo Jung Lee,Xueli Bai,Yoo-Seok Yoon,Yin-Mo Yang,Keun Soo Ahn,Chunhui Yuan,Hyeon Kook Lee,Bei Sun,Eun Kyu Park,Seung Eun Lee,Sunghwa Kang,Wenhui Lou,Sang-Jae Park

DOI: https://doi.org/10.3390/cancers14041038

2022-01-01

Cancers

Abstract:Several treatment guidelines for sporadic, nonmetastatic nonfunctioning neuroendocrine tumors of the pancreas (NF-pNETs) have recommended resection, however, tumors ≤ 2 cm do not necessarily need surgery. This study aims to establish a surgical treatment plan for NF-pNETs ≤ 2 cm. From 2000 to 2017, 483 patients who underwent resection for NF-pNETs ≤ 2 cm in 18 institutions from Korea and China were enrolled and their medical records were reviewed. The median age was 56 (range 16–80) years. The 10-year overall survival rate (10Y-OS) and recurrence-free survival rate (10Y-RFS) were 89.8 and 93.1%, respectively. In multivariable analysis, tumor size (>1.5 cm; HR 4.28, 95% CI 1.80–10.18, p = 0.001) and nodal metastasis (HR 3.32, 95% CI 1.29–8.50, p = 0.013) were independent adverse prognostic factors for OS. Perineural invasion (HR 4.36, 95% CI 1.48–12.87, p = 0.008) and high Ki-67 index (≥3%; HR 9.06, 95% CI 3.01–27.30, p < 0.001) were independent prognostic factors for poor RFS. NF-pNETs ≤ 2 cm showed unfavorable prognosis after resection when the tumor was larger than 1.5 cm, Ki-67 index ≥ 3%, or nodal metastasis was present. NF-pNET patients with tumors ≤ 1.5 cm can be observed if the preoperative Ki-67 index is under 3%, and if nodal metastasis is not suspected in preoperative radiologic studies. These findings support the clinical use to make decisions about small NF-pNETs.
Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors

Akash Kartik,Valerie L. Armstrong,Chee-Chee Stucky,Nabil Wasif,Zhi Ven Fong

DOI: https://doi.org/10.3390/cancers16081501

2024-04-14

Cancers

Abstract:The incidence of pancreatic neuroendocrine tumors (PNETs) is on the rise primarily due to the increasing use of cross-sectional imaging. Most of these incidentally detected lesions are non-functional PNETs with a small proportion of lesions being hormone-secreting, functional neoplasms. With recent advances in surgical approaches and systemic therapies, the management of PNETs have undergone a paradigm shift towards a more individualized approach. In this manuscript, we review the histologic classification and diagnostic approaches to both functional and non-functional PNETs. Additionally, we detail multidisciplinary approaches and surgical considerations tailored to the tumor's biology, location, and functionality based on recent evidence. We also discuss the complexities of metastatic disease, exploring liver-directed therapies and the evolving landscape of minimally invasive surgical techniques.

oncology
Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

ZHAO Ting,CHEN Jionghuang,CAO Liping

DOI: https://doi.org/10.3969/j.issn.1000-8179.2017.16.354

2017-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective: To investigate the clinical characteristics, diagnosis, treatment, and prognostic factors of pancreatic neuroendocrine neoplasms (PNENs). Methods: From August 2004 to August 2016, the clinical data of 63 patients with PNENs in the Sir Run Run Shaw Hospital, an affiliate of the Zhejiang University School of Medicine, were retrospectively analyzed. The data included age, gender, function, tumor location, tumor size, pathological characteristics, lymph nodes, metastasis, and treatment. Association of these factors with PNEN prognosis was proven by univariate analysis and multivariate analysis. Results: In our study, the patients' overall survival time was between 5 and 127 months; the median time was about 46.6 months. Moreover, the survival rates in three years and five years are 88.8％ and 84.1％ respectively. Univariate analysis showed that factors such as lymph node metastasis, liver metastasis, vascular invasion, TNM staging and pathological grading, and radical operation were associated with prognosis (P<0.05). We did not prove any of the factors to be an independent factor associated with poor short-term outcome by multivariate analysis. Conclusion: PNENs are rare low-grade malignant tumors with heterogeneity, which is why they can be erroneously diagnosed. AJCC TNM staging in 2017 and the WHO pathological classification in 2010 can actively guide the prognosis evaluation. The lymph node metastasis, liver metastasis,and vascular invasion affected the prognosis of PNENs. Patients with radical operation had improved prognosis.
[Surgical Treatment for Pancreatic Neuroendocrine Neoplasmas].

Junli Wu,Feng Guo,Jishu Wei,Zipeng Lu,Jianmin Chen,Wentao Gao,Qiang Li,Kuirong Jiang,Cuncai Dai,Yi Miao

DOI: https://doi.org/10.3785/j.issn.1008-9292.2016.01.05

2016-01-01

Abstract:Pancreatic neuroendocrine neoplasmas (PNENs) are classified into functioning & non-functioning tumors. The radical surgery is the only effective way for the cure & long-term survival. For the locoregional resectable tumors, the surgical resection is the first choice of treatment; the surgical procedures include local resection (enucleation) and standard resection. For the insulinomas and non-functioning tumors less than 2 cm, local resection (enucleation),distal pancreatectomy with spleen-preservation or segmental pancreatectomy are the commonly selected procedures. The radical resections with regional lymph nodes dissection, including pancreaticoduodenectomy, distal pancreatectomy and middle segmental pancreatectomy, should be applied for tumors more than 2 cm or malignant ones. For the locoregional advanced or unresectable functioning tumors, debulking surgery should be performed and more than 90% of the lesions including primary and metastatic tumors should be removed; for the non-functioning tumors, if complicated with biliary & digestive tract obstruction or hemorrhage, the primary tumors should be resected. The liver is the most frequent site of metastases for PNENs and three types of metastases are defined. For typeⅠmetastasis, patients are recommended for surgery if there are no contraindications; For type II metastasis, debulking surgery should be applied and at least 90% of metastatic lesions should be resected, and for patients with primary tumors removed and no extrahepatic metastases, or for patients with well-differentiated (G1/G2) tumors, liver transplantation may be indicated. For the unresectable type Ⅲ metastasis, multiple adjuvant therapies should be chosen.
Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors

Shadin Ghabra,Bhavishya Ramamoorthy,Stephen G Andrews,Samira M Sadowski

DOI: https://doi.org/10.1016/j.suc.2024.02.019

Abstract:Pancreatic neuroendocrine tumors (PNETs) arise from neuroendocrine cells and are a rare class of heterogenous tumors with increasing incidence. The diagnosis, staging, treatment, and prognosis of PNETs depend heavily on identifying the histologic features and biological mechanisms. Here, the authors provide an overview of the diagnostic workup (biomarkers and imaging), grade, and staging of PNETs. The authors also explore associated genetic mutations and molecular pathways and describe updated guidelines on surgical and systemic treatment modalities.
Surgical management of pancreatic neuroendocrine tumor

Wen-hui LOU

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2012.04.007

2012-01-01

Abstract:Pancreatic neuroendocrine tumor (pNET) accounts for about 2％ of all malignant pancreatic tumors.According to presence or absence of specific hormone related symptoms,pNET is classified as functional and non-functional.About 75％ of pNET is non-functional.Surgery is the only potential treatment that cures pNET.Before operation,localization of primary tumor is very important.For localized lesions,pancreaticoduodenectomy,segmental pancreatectomy,distal pancreatectomy or enucleation could be chosen according to the site of primary tumor.For metastatic pNET,if the primary lesion and metastatic lesions could be resected simultaneously,aggressive approach is an optimal choice and better clinical outcome could be achieved.For those with big multiple metastatic lesions,especially in the liver,debulking operation should be considered when more than 90％ metastatic lesions could be resected,for debulking operation could improve the survival and quality of life of those patients.Liver transplantation should be reserved to patients with no extra-hepatic metastasis and tumor is stable with low grade,while R0 resection could be achieved for primary lesion.\r\n\r\nKey words: \r\nPancreatic neoplasms; Surgical management

Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors

Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An analysis of the US SEER Database and a Chinese Single-center Cohort

Consensus of Clinical Diagnosis and Treatment for Non-Functional Pancreatic Neuroendocrine Neoplasms with Diameter <2 Cm

Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Clinical Analysis and Comprehensive Treatment of Nonfunctional Pancreatic Neuroendocrine Tumor with Liver Metastases

The surgical managements for neuroendocrine tumors of the pancreas

Risk Of Malignancy And Prognosis Of Sporadic Resected Small (<= 2 Cm) Nonfunctional Pancreatic Neuroendocrine Tumors

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Advances in Management of Nonfunctional Pancreas Neuroendocrine Tumors

Analysis of the Clinical Features of 20 Cases of Non-Functioning Pancreatic Neuroendocrine Tumors

Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors

Clinical Efficacy of the Laparoscopic Resection for Pancreatic Neuroendocrine Neoplasms

Minimal Invasive Surgery in the Treatment of Neuroendocrine Tumors of the Pancreas

Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature

Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: an International Study Using Multi-Institutional Registries

Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors

Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

[Surgical Treatment for Pancreatic Neuroendocrine Neoplasmas].

Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors

Surgical management of pancreatic neuroendocrine tumor